Diagnos Laboratorium Utama PT Tbk Cash Flow Conversion Efficiency
Diagnos Laboratorium Utama PT Tbk cash flow conversion efficiency. Based on the latest financial reports, Diagnos Laboratorium Utama PT Tbk (DGNS) has a cash flow conversion efficiency ratio of 0.008x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp1.52 Billion ≈ $88.96K USD) by net assets (Rp194.00 Billion ≈ $11.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Diagnos Laboratorium Utama PT Tbk (2017–2024)
Cash flow conversion efficiency of Diagnos Laboratorium Utama PT Tbk from 2017 to 2024. This chart illustrates how Diagnos Laboratorium Utama PT Tbk's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Diagnos Laboratorium Utama PT Tbk stock price today for real-time trading data and today's change.
Diagnos Laboratorium Utama PT Tbk Cash Flow Conversion Ratio Explained
Diagnos Laboratorium Utama PT Tbk cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Diagnos Laboratorium Utama PT Tbk Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Diagnos Laboratorium Utama PT Tbk ranked by their cash flow conversion efficiency. Also see market value of Diagnos Laboratorium Utama PT Tbk for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alpha Exploration Ltd
V:ALEX
|
-0.010x |
|
Personal Assets Trust plc
LSE:PNL
|
-0.004x |
|
Plantynet Co. Ltd
KQ:075130
|
0.028x |
|
Manaksia Aluminium Company Limited
NSE:MANAKALUCO
|
-0.083x |
|
9F Inc
NASDAQ:JFU
|
0.038x |
|
Korean Drug Co. Ltd
KQ:014570
|
0.024x |
|
Sidiz Inc
KO:134790
|
0.077x |
|
Allied Industrial Ltd
TWO:4702
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Diagnos Laboratorium Utama PT Tbk (2017–2024)
The table below shows the annual cash flow conversion efficiency of Diagnos Laboratorium Utama PT Tbk from 2017 to 2024. Review Diagnos Laboratorium Utama PT Tbk free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp196.13 Billion ≈ $11.49 Million |
Rp27.30 Billion ≈ $1.60 Million |
0.139x | +106.49% |
| 2023-12-31 | Rp195.59 Billion ≈ $11.46 Million |
Rp13.18 Billion ≈ $772.50K |
0.067x | +335.77% |
| 2022-12-31 | Rp210.43 Billion ≈ $12.33 Million |
Rp-6.02 Billion ≈ $-352.51K |
-0.029x | -109.80% |
| 2021-12-31 | Rp201.80 Billion ≈ $11.82 Million |
Rp58.87 Billion ≈ $3.45 Million |
0.292x | +10.19% |
| 2020-12-31 | Rp99.07 Billion ≈ $5.80 Million |
Rp26.23 Billion ≈ $1.54 Million |
0.265x | +9.86% |
| 2019-12-31 | Rp46.46 Billion ≈ $2.72 Million |
Rp11.20 Billion ≈ $656.06K |
0.241x | -62.25% |
| 2018-12-31 | Rp13.27 Billion ≈ $777.31K |
Rp8.47 Billion ≈ $496.20K |
0.638x | +388.54% |
| 2017-12-31 | Rp3.22 Billion ≈ $188.58K |
Rp-712.00 Million ≈ $-41.72K |
-0.221x | -- |
About Diagnos Laboratorium Utama PT Tbk
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want t… Read more